Anbio Biotechnology (NASDAQ:NNNN) Shares Down 10.2% – Here’s Why

Anbio Biotechnology (NASDAQ:NNNN)’s stock price dropped 10.2% during trading on Wednesday . The stock traded as low as $26.40 and last traded at $26.23. Approximately 37,933 shares traded hands during trading, a decline of 21% from the average daily volume of 48,034 shares. The stock had previously closed at $29.20.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Anbio Biotechnology Stock Down 8.9%

The company’s fifty day moving average is $25.19.

Anbio Biotechnology (NASDAQ:NNNN) last issued its earnings results on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.